BeiGene, Ltd. (NASDAQ:BGNE) Forecasted to Post Q2 2024 Earnings of ($3.13) Per Share

BeiGene, Ltd. (NASDAQ:BGNEFree Report) – Equities researchers at Leerink Partnrs issued their Q2 2024 earnings per share estimates for BeiGene in a report released on Monday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($3.13) for the quarter. The consensus estimate for BeiGene’s current full-year earnings is ($7.05) per share. Leerink Partnrs also issued estimates for BeiGene’s Q3 2024 earnings at ($2.94) EPS and Q4 2024 earnings at ($2.99) EPS.

Other equities research analysts have also recently issued reports about the stock. Citigroup decreased their price objective on shares of BeiGene from $290.00 to $285.00 and set a “buy” rating for the company in a research report on Thursday, October 26th. StockNews.com raised BeiGene from a “sell” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $185.00 price objective on shares of BeiGene in a report on Tuesday. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $261.40.

Check Out Our Latest Stock Analysis on BGNE

BeiGene Trading Down 3.3 %

NASDAQ BGNE opened at $142.88 on Wednesday. BeiGene has a 52 week low of $132.95 and a 52 week high of $272.49. The firm has a 50 day moving average of $170.73 and a two-hundred day moving average of $183.94. The company has a quick ratio of 2.91, a current ratio of 3.16 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $13.63 billion, a PE ratio of -15.43 and a beta of 0.60.

BeiGene (NASDAQ:BGNEGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.38) by $5.39. BeiGene had a negative return on equity of 23.83% and a negative net margin of 43.53%. The business had revenue of $781.30 million during the quarter, compared to analysts’ expectations of $596.75 million. During the same quarter last year, the business posted ($5.39) EPS. The business’s quarterly revenue was up 101.6% compared to the same quarter last year.

Institutional Trading of BeiGene

A number of large investors have recently bought and sold shares of BGNE. Baillie Gifford & Co. raised its stake in shares of BeiGene by 17.9% during the third quarter. Baillie Gifford & Co. now owns 3,871,598 shares of the company’s stock worth $696,384,000 after purchasing an additional 588,294 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of BeiGene by 68.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 775,857 shares of the company’s stock worth $167,222,000 after purchasing an additional 314,764 shares during the last quarter. BlackRock Inc. raised its stake in shares of BeiGene by 23.1% during the second quarter. BlackRock Inc. now owns 868,757 shares of the company’s stock worth $154,899,000 after purchasing an additional 162,949 shares during the last quarter. Capital Group Private Client Services Inc. raised its stake in shares of BeiGene by 74.2% during the first quarter. Capital Group Private Client Services Inc. now owns 275,197 shares of the company’s stock worth $51,902,000 after purchasing an additional 117,231 shares during the last quarter. Finally, State Street Corp raised its stake in shares of BeiGene by 60.1% during the first quarter. State Street Corp now owns 266,211 shares of the company’s stock worth $57,539,000 after purchasing an additional 99,974 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

(Get Free Report)

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Featured Articles

Earnings History and Estimates for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.